Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.

Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M.

Int J Cancer. 2012 Jul 15;131(2):396-405. doi: 10.1002/ijc.26377. Epub 2011 Oct 20.

2.

Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.

King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG.

Breast Cancer Res. 2004;6(5):R478-87. Epub 2004 Jun 28.

3.

Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.

Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, Bockhorn M.

J Surg Res. 2012 Sep;177(1):e15-20. doi: 10.1016/j.jss.2012.02.013. Epub 2012 Mar 30.

PMID:
22482754
4.

Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.

Donizy P, Zietek M, Halon A, Leskiewicz M, Kozyra C, Matkowski R.

Diagn Pathol. 2015 Jul 2;10:86. doi: 10.1186/s13000-015-0331-z.

5.

Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer.

Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Taniguchi T, Yokoi K, Osada H, Sekido Y.

J Surg Res. 2013 Jan;179(1):24-32. doi: 10.1016/j.jss.2012.08.044. Epub 2012 Sep 7.

PMID:
22985775
6.

ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.

Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M.

J Surg Res. 2011 Oct;170(2):226-32. doi: 10.1016/j.jss.2011.06.002. Epub 2011 Jul 2.

PMID:
21816425
7.

Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation.

Ye M, Du YL, Nie YQ, Zhou ZW, Cao J, Li YF.

Mol Med Rep. 2015 Mar;11(3):2004-12. doi: 10.3892/mmr.2014.2933. Epub 2014 Nov 12.

PMID:
25395097
8.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K.

Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.

PMID:
20972617
9.

MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.

Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R.

Oncology. 2005;68(4-6):462-70. Epub 2005 Jul 13.

PMID:
16024937
10.

Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.

Ihnen M, Köhler N, Kersten JF, Milde-Langosch K, Beck K, Höller S, Müller V, Witzel I, Jänicke F, Kilic E.

Dis Markers. 2010;28(2):71-8. doi: 10.3233/DMA-2010-0685.

11.

Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.

Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.

Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.

12.

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.

Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, Weitz J.

Br J Cancer. 2009 Aug 4;101(3):457-64. doi: 10.1038/sj.bjc.6605136. Epub 2009 Jul 14.

13.

Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.

Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G.

J Clin Pathol. 2006 Apr;59(4):403-9. Epub 2006 Feb 16.

14.

Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer.

Vashist YK, Effenberger KE, Vettorazzi E, Riethdorf S, Yekebas EF, Izbicki JR, Pantel K.

Ann Surg. 2012 Jun;255(6):1105-12. doi: 10.1097/SLA.0b013e3182565b0b.

PMID:
22580852
15.

Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.

Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K.

Breast Cancer Res Treat. 2008 Dec;112(3):419-27. doi: 10.1007/s10549-007-9879-y. Epub 2008 Jan 3.

PMID:
18172759
16.

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.

Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Müller V, Mahner S, Jänicke F, Woelber L, Milde-Langosch K.

BMC Cancer. 2012 Apr 4;12:140. doi: 10.1186/1471-2407-12-140.

17.

ALCAM (CD166) expression and serum levels in pancreatic cancer.

Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M.

PLoS One. 2012;7(6):e39018. doi: 10.1371/journal.pone.0039018. Epub 2012 Jun 20.

18.

ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer.

Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, Sauliunaite D, De Oliveira T, Friess H, Kleeff J.

J Surg Oncol. 2010 Jun 1;101(7):564-9. doi: 10.1002/jso.21538.

PMID:
20461761
19.

ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.

Jezierska A, Matysiak W, Motyl T.

Med Sci Monit. 2006 Aug;12(8):BR263-73. Epub 2006 Jul 12.

PMID:
16865058
20.

Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.

Chaker S, Kak I, MacMillan C, Ralhan R, Walfish PG.

Thyroid. 2013 Feb;23(2):201-8. doi: 10.1089/thy.2012.0405.

PMID:
23148625
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk